[HTML][HTML] Lymphoma epidemiology in Korea and the real clinical field including the Consortium for Improving Survival of Lymphoma (CISL) trial
KH Yoo, H Lee, C Suh, CISL - International Journal of Hematology, 2018 - Springer
Lymphomas are a heterogeneous group of disease entities with well-defined clinical,
morphological, immunophenotypic, and cytogenetic characteristics. Moreover, regional and …
morphological, immunophenotypic, and cytogenetic characteristics. Moreover, regional and …
Results of a large retrospective analysis of the effect of intended dose intensity of R‐CHOP on outcome in a cohort of consecutive, unselected elderly patients with de …
Hampshire, PA, Welch, CA, McCrossan, LA, Francis, K. & Harrison, DA (2009) Admission
factors associated with hospital mortality in patients with haematological malignancy …
factors associated with hospital mortality in patients with haematological malignancy …
Risk and subtypes of secondary primary malignancies in diffuse large B‐cell lymphoma survivors change over time based on stage at diagnosis
Background Previous studies have shown an increased risk of secondary primary
malignancies (SPMs) after diffuse large B‐cell lymphoma (DLBCL) treatment. Whether stage …
malignancies (SPMs) after diffuse large B‐cell lymphoma (DLBCL) treatment. Whether stage …
Persistent disparities among patients with T-cell non-Hodgkin lymphomas and B-cell diffuse large cell lymphomas over 40 years: a SEER database review
Background As of 2013, more than 550,000 people are living with non-Hodgkin lymphoma
(NHL). Patients and Methods We undertook a large Surveillance Epidemiology and End …
(NHL). Patients and Methods We undertook a large Surveillance Epidemiology and End …
[HTML][HTML] Mortality rate of lymphoma in China, 2013–2020
W Liu, J Qi, J Liu, Y Song, L Wang, M Zhou, J Ma… - Frontiers in …, 2022 - frontiersin.org
Lymphoma is a malignant disease that threatens human health and imposes a significant
burden on the society burden; however, there are limited accurate mortality data on …
burden on the society burden; however, there are limited accurate mortality data on …
Trends in non‐Hodgkin lymphoma mortality rate in Japan and the United States: A population‐based study
Y Usui, H Ito, K Katanoda, T Matsuda, Y Maeda… - Cancer …, 2023 - Wiley Online Library
Characterizing trends in mortality rates with consideration of trends in incidence rates at the
population level could help identify unmet needs in public health and provide essential …
population level could help identify unmet needs in public health and provide essential …
Outcomes of cardiac diffuse large B-cell lymphoma (DLBCL) in the rituximab era
T Al-Juhaishi, SG Al-Kindi - International Journal of Cardiology, 2021 - Elsevier
Background Cardiac diffuse large B-cell lymphoma (cDLBCL) is an extremely rare disease.
Introduction of rituximab has significantly improved survival in non-cardiac DLBCL, but there …
Introduction of rituximab has significantly improved survival in non-cardiac DLBCL, but there …
[HTML][HTML] Mediation analyses of socioeconomic factors determining racial differences in the treatment of diffuse large B-cell lymphoma in a cohort of older adults
JS Guadamuz, K Ozenberger, DM Qato, NY Ko… - Medicine, 2019 - journals.lww.com
Despite near universal health coverage under Medicare, racial disparities persist in the
treatment of diffuse large B-cell lymphoma (DLBCL) among older patients in the United …
treatment of diffuse large B-cell lymphoma (DLBCL) among older patients in the United …
Efficacy and tolerability of rituximab and reduced-dose cyclophosphamide, doxorubicin, vincristine, and prednisolone therapy for elderly patient with diffuse large B …
K Kayamori, K Shono, M Onoda, A Yokota - Hematology, 2019 - Taylor & Francis
Objectives: Chemoimmunotherapy with cyclophosphamide, doxorubicin, vincristine, and
prednisolone combined with rituximab (R-CHOP) is currently the first-line therapy for diffuse …
prednisolone combined with rituximab (R-CHOP) is currently the first-line therapy for diffuse …
Prevalencia y factores asociados a respuesta completa a la primera línea de quimioterapia en pacientes con diagnóstico de linfoma difuso de células b, en el Instituto …
B Maldonado - ATENEO, 2022 - colegiomedicosazuay.ec
Introducción: Los linfomas son un grupo heterogéneo de trastornos linfoproliferativos que se
clasifican de acuerdo a su histología, de los cuales, los linfomas de células B representan el …
clasifican de acuerdo a su histología, de los cuales, los linfomas de células B representan el …